The prevalence of SPNM in myositis was estimated to be 2.2–7.6% and tends to occur in DM patients with RP-ILD, anti-MDA5 antibody, CADM diagnosis, low creatine kinase (CK) level, and patients with cutaneous ulcers (2, 3). Here, IFIH1 is linked to clinically amyopathic dermatomyositis.